PL70900B1 - Benzodiazepine derivatives processes for producing them and compo sitions containing them[gb1309948a] - Google Patents
Benzodiazepine derivatives processes for producing them and compo sitions containing them[gb1309948a] Download PDFInfo
- Publication number
- PL70900B1 PL70900B1 PL1971145964A PL14596471A PL70900B1 PL 70900 B1 PL70900 B1 PL 70900B1 PL 1971145964 A PL1971145964 A PL 1971145964A PL 14596471 A PL14596471 A PL 14596471A PL 70900 B1 PL70900 B1 PL 70900B1
- Authority
- PL
- Poland
- Prior art keywords
- benzodiazepinone
- dihydro
- chloro
- formula
- radical
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 12
- 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 title claims description 10
- 229940053197 benzodiazepine derivative antiepileptics Drugs 0.000 title claims description 8
- 239000000203 mixture Substances 0.000 title claims description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 20
- 150000003839 salts Chemical class 0.000 claims abstract description 11
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 6
- -1 alkyl radical Chemical class 0.000 claims description 39
- 125000004432 carbon atom Chemical group C* 0.000 claims description 13
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 9
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 4
- WZKSXHQDXQKIQJ-UHFFFAOYSA-N F[C](F)F Chemical compound F[C](F)F WZKSXHQDXQKIQJ-UHFFFAOYSA-N 0.000 claims description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 claims description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 4
- 150000005840 aryl radicals Chemical class 0.000 claims description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- ZFFBIQMNKOJDJE-UHFFFAOYSA-N 2-bromo-1,2-diphenylethanone Chemical compound C=1C=CC=CC=1C(Br)C(=O)C1=CC=CC=C1 ZFFBIQMNKOJDJE-UHFFFAOYSA-N 0.000 claims description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- AFRJJFRNGGLMDW-UHFFFAOYSA-N lithium amide Chemical compound [Li+].[NH2-] AFRJJFRNGGLMDW-UHFFFAOYSA-N 0.000 claims description 2
- 229910000103 lithium hydride Inorganic materials 0.000 claims description 2
- SIAPCJWMELPYOE-UHFFFAOYSA-N lithium hydride Chemical compound [LiH] SIAPCJWMELPYOE-UHFFFAOYSA-N 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 229910000104 sodium hydride Inorganic materials 0.000 claims description 2
- 239000008096 xylene Substances 0.000 claims description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical group [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims 1
- 150000003254 radicals Chemical class 0.000 claims 1
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 claims 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 claims 1
- 239000012312 sodium hydride Substances 0.000 claims 1
- 239000011877 solvent mixture Substances 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 abstract description 4
- 150000002367 halogens Chemical class 0.000 abstract description 4
- 239000003158 myorelaxant agent Substances 0.000 abstract description 4
- 229940049706 benzodiazepine Drugs 0.000 abstract description 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 3
- 230000000147 hypnotic effect Effects 0.000 abstract description 3
- 229910052757 nitrogen Inorganic materials 0.000 abstract description 3
- 239000000932 sedative agent Substances 0.000 abstract description 3
- 239000003326 hypnotic agent Substances 0.000 abstract description 2
- 229940035363 muscle relaxants Drugs 0.000 abstract description 2
- 229940125723 sedative agent Drugs 0.000 abstract description 2
- 230000002048 spasmolytic effect Effects 0.000 abstract description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical group C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 abstract 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 150000001557 benzodiazepines Chemical class 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 abstract 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 abstract 1
- 230000001590 oxidative effect Effects 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 238000006049 ring expansion reaction Methods 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 7
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 239000000460 chlorine Substances 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 239000003513 alkali Substances 0.000 description 4
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- ATHHXGZTWNVVOU-UHFFFAOYSA-N N-methylformamide Chemical compound CNC=O ATHHXGZTWNVVOU-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- WPWHSFAFEBZWBB-UHFFFAOYSA-N 1-butyl radical Chemical group [CH2]CCC WPWHSFAFEBZWBB-UHFFFAOYSA-N 0.000 description 1
- AVFZOVWCLRSYKC-UHFFFAOYSA-N 1-methylpyrrolidine Chemical compound CN1CCCC1 AVFZOVWCLRSYKC-UHFFFAOYSA-N 0.000 description 1
- IQHSSYROJYPFDV-UHFFFAOYSA-N 2-bromo-1,3-dichloro-5-(trifluoromethyl)benzene Chemical group FC(F)(F)C1=CC(Cl)=C(Br)C(Cl)=C1 IQHSSYROJYPFDV-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- JAPZNEGAIRTCQX-UHFFFAOYSA-N ClC=1N[N+](=CC=CC=1)[O-] Chemical compound ClC=1N[N+](=CC=CC=1)[O-] JAPZNEGAIRTCQX-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- AHVYPIQETPWLSZ-UHFFFAOYSA-N N-methyl-pyrrolidine Natural products CN1CC=CC1 AHVYPIQETPWLSZ-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- BQOWUDKEXDCGQS-UHFFFAOYSA-N [CH]1CCCC1 Chemical compound [CH]1CCCC1 BQOWUDKEXDCGQS-UHFFFAOYSA-N 0.000 description 1
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 1
- 150000008046 alkali metal hydrides Chemical class 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- UYXAWHWODHRRMR-UHFFFAOYSA-N hexobarbital Chemical compound O=C1N(C)C(=O)NC(=O)C1(C)C1=CCCCC1 UYXAWHWODHRRMR-UHFFFAOYSA-N 0.000 description 1
- 229960002456 hexobarbital Drugs 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- YWOITFUKFOYODT-UHFFFAOYSA-N methanol;sodium Chemical compound [Na].OC YWOITFUKFOYODT-UHFFFAOYSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- NHKJPPKXDNZFBJ-UHFFFAOYSA-N phenyllithium Chemical compound [Li]C1=CC=CC=C1 NHKJPPKXDNZFBJ-UHFFFAOYSA-N 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
- C07D243/24—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
- C07D243/24—Oxygen atoms
- C07D243/26—Preparation from compounds already containing the benzodiazepine skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
- C07D243/24—Oxygen atoms
- C07D243/28—Preparation including building-up the benzodiazepine skeleton from compounds containing no hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
- C07D243/24—Oxygen atoms
- C07D243/30—Preparation including building-up the benzodiazepine skeleton from compounds already containing hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
- C07D243/24—Oxygen atoms
- C07D243/30—Preparation including building-up the benzodiazepine skeleton from compounds already containing hetero rings
- C07D243/36—Preparation including building-up the benzodiazepine skeleton from compounds already containing hetero rings containing an indole or hydrogenated indole ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Sposób wytwarzania nowych pochodnych benzodwuazepiny Przedmiotem wynalazku jest sposób wytwarzania nowych pochodnych benzodwuazepiny, podstawionych w pozycji 1 o wzorze 1, w którym Rt oznacza atom wodoru, chlorowca, grupe nitrowa, cyjanowa, nizszy rodnik alkoksylowy lub rodnik trójfluorometylowy, R2 oznacza grupe pirydylowa lub grupe o wzorze 2, w którym R5 i R6 oznaczaja niezaleznie od siebie atom wodoru, chlorowca, nizszy rodnik alkilowy o 1 -2 atomach wegla lub rodnik trójfluorometylowy, R3 oznacza atom wodoru lub nizszy rodnik alkilowy o 1—4 atomach wegla, R4 oznacza nizszy rodnik alkilowy o 1-4 atomach wegla, rodnik cykloalkilowy o 3—6 atomach wegla, rodnik cykloalkiloalkilowy, w którym czesc cykloalkilowa zawiera 3—6 atomów wegla, a czesc alkilowa 1—4 atomów wegla, rodnik arylowy lub rodnik aryloalkilowy, m jest równe 1 lub 2, a n jest liczba calkowita 1-4 oraz ich soli.W zwiazkach o wzorze 1 atom chlorowca moze oznaczac atom fluoru, chloru, bromu lub jodu; rodnik alkilowy moze miec lancuch prosty lub rozgaleziony; nizszy rodnik alkilowy moze na przyklad oznaczac rodnik metylowy, etylowy, n-propylowy, izopropylowy, n-butylowy i lll-rzed.butylowy; nizszy rodnik alkoksylowy moze oznaczac na przyklad rodnik metoksylowy, etoksylowy, n-propoksylowy, izopropoksylowy, n-butoksylowy i lll-rzed.butoksylowy; rodnik cykloalkilowy moze oznaczac na przyklad rodnik cyklopropylowy, cykIobuty Iowy, cykloheksylowy i cyklopentylowy; rodnik cykloalkiloalkilowy moze oznaczac na przyklad rodnik cyklopropylometylowy, cyklobutylometylowy, cyklobutylometylowy, cyklopentylometylowy, cykloheksylometylowy i cykloheksyloetylowy; rodnik arylowy moze oznaczac na przyklad rodnik fenylowy, jedno-lub dwupodstawiony rodnik fenylowy, w którym podstawnikami w pierscieniu fenylowym moga byc atomy chlorowca takie jak atom chloru, fluoru, bromu lub jodu, nizszy rodnik alkilowy, taki jak metylowy lub etylowy, nizszy rodnik alkoksylowy, taki jak metoksylowy lub etoksylowy, grupa nitrowa i rodnik trójfluorometylowy; rodnik aryloalkilowy moze oznaczac na przyklad rodnik benzylowy i fenyloetylowy; rodnik alkenylowy -CnH2n- moze byc rodnikiem alkenylowym o prostym lub rozgalezionym lancuchu o 1—4 atomach wegla, na przyklad takim, jak rodnik etylenowy, 1-metyloetylenowyf 2-metyloetylenowy, trójmetylenowy, 1-metylotrójmety!enowy i 2-metylotrójmetylenowy.2 70 900 Pochodne benzodwuazepiny o wzorze 1, podstawione w pozycji 1 oraz ich sole sa zwiazkami nowymi.Nieoczekiwanie stwierdzono, ze zwiazki te, a szczególnie zwiazki o wzorze ogólnym 1a, w którym Ri, R4, R5, R6 i m maja znaczenie podane powyzej, a n' jest równe 2 lufo 3 oraz ich dopuszczalne farmaceutycznie sole z kwasami nieorganicznymi i organicznymi maja cenne wlasciwosci farmakologiczne, szczególnie uspokajajace, rozluzniajace miesnie, spazmolityczne i nasenne.Sposób wytwarzania nowych pochodnych benzodwuazepiny o wzorze 1 wedlug wynalazku polega na reakcji niepodstawionych w pozycji 1 foenzodwuazepin o wzorze 3, w którym R1# R2 i R3 maja wyzej podane znaczenie ze zwiazkiem o wzorze Cl—CnH2n—S/0/m—R4, w którym R4 min maja znaczenie podane powyzej.Reakcje miedzy zwiazkiem o wzorze 3 a zwiazkiem o wzorze Cl—CnH2n—S/O/m—R4 prowadzi sie w obecnosci srodka alkalicznego lub zwiazek o wzorze 3 poddaje sie reakcji ze srodkiem alkalicznym, przy czym otrzymuje sie sól metalu, która nastepnie poddaje sie reakcji ze zwiazkiem o wzorze Cl—CnH2n_S/0/m—R4.Przykladami srodków alkalicznych sa wodorki metali alkalicznych, takie jak wodorek sodowy lub litowy, wodorotlenek metalu alkalicznego, taki jak wodorotlenek potasowy, amidek metalu alkalicznego, taki jak amidek sodowy, amidek potasowy lub amidek litowy, alkiloalkalia takie jak butylolit, fenyloalkalia, takie jak fenylolit, alkoholan metalu alkalicznego, taki jak metanolan sodu, etanolan scdu, trzeciorzedowy butanolan potasu i podobne. Reakcje prowadzi sie w rozpuszczalniku lub mieszaninie rozpuszczalników organicznych. Odpowied¬ nimi rozpuszczalnikami sa: benzen, toulen, ksylen, dwumetyloformamid, dwumetyloacetamid, eter dwufenylo- wy, eter dwumetylowy glikolu dwuetylenowego, dwumetylosulfotlenek, metyloetyloketon, N-metylopirolidyna itp. oraz ich mieszaniny. Zakres temperatury, w której prowadzi sie reakcje zawiera sie miedzy temperatura pokojowa i temperatura wrzenia zastosowanego rozpuszczalnika.Sposobem wedlug wynalazku otrzymuje sie na przyklad nastepujace zwiazki: 1-/j3-metylosulfonyloetylo/-5-fenylo-7-chloro-1,3-dwuwodoro-2H-1,4-benzodwuazepinon-2, 1-//3-metylosulfonyloetylo/-5-fenylo-7-cyjano-1,3-dwuwodoro-2H-1,4-benzodwuazepinon-2, 1-/j3-metylosulfonyloetylo/-5-fenylo-7-nitro-1,3-dwuwodoro-2H-1,4-benzodwuazepinon*2, 17j3-metylosulfonyloetylo/-5-fenylo-7-metoksylo-1,3-dwuwodoro-2H-1,4-benzodwuazepinon-2, l7j3-metylosulfonyloetylo/-5-fenylo-7-trójfluorometylo-1,3-dwuwodoro-2H-1,4-benzodwuazepinon-2, 170-metylosulfony loetylo/-5-fenylo-7-bromo-1,3-dwuwodoro-2H-1,4-benzodwuazepinon-2, 1-/P-metylosulfonyloetylo/-5-fenylo-1,3-dwuwodoro-2H-1,4-benzodwuazepinon-2, 1-/j3-metylosulfonyloetylo/-3-metylo-5-fenylo-7-chloro-1,3-dwuwodoro-2H-1,4-benzodwuazepJnon-2, 1 7/3-metylosulfonyloetylo/-572'-pirydylo/-7-ch lor j-1,3-dwuwodoro-2H-1,4-benzodwuazepinon-2, 1-/j3-metylosulfonyloetylo/-5-/o-fluorofenylo/-7-chloro-1,3-dwuwodoro-2H-1,4-benzodwuazepinon-2, 17j3-metylosulfonyloetylo/-572'-pirydylo/-7-bromo-1,3-dwuwodoro-2H-1,4-benzodwuazepinon-2, 17]3-metylosulfonyloetylo/-5-/0-chlorofenyloA7-chloro-1,3-dwuwodoro-2H-1,4-benzodwuazepinon-2, l7|3-metylosulfonyloetylo/-57o-tolilo/-7-chloro-1,3-dwuwodoro-2H-1,4-benzodwuazepinon-2, 170-metylosulfonyloetylo/-57o-chlorofenylo/-7-nitro-1,3-dwuwodoro-2H-1,4-benzodwuazepinon-2, 17P-metylosulfonyloetylo/-57o-trójfluorometylofenylo/-7-chloro-1,3-dwuwodoro-2H-1,4-benzodwuazepinon-2, ^/jS-etylosulfonyloetyloAS-fenylo^-chloro-l^-dwuwodoro^H-l^-benzodwuazepinon^, 17/J-etylosulfonyloetylo/-5-fenylo-7-cyjano-1,3-dwuwodoro-2H-1,4-benzodwuazepinon-2, 170-etylosulfonyloetylo/-5-fenylo-7-nitro-1,3-dwuwodoro-2H-1f4-benzodwuazepinon-2, l7^-etylosulfonyloetylo/-5-fenylo-7-trójfluorometylo-1,3-dwuwodoro-2H-1,4-benzodwuazepinon-2, 17jS-etylosulfonyloetylo/-5*fenylo-7-bromo-1,3-dwuwodoro-2H-1,4-benzodwuazepinon-2, l7j3-etylosulfonyloetylo/-57o-fluorofenylo/-7-chloro-1,3-dwuwodoro-2H-1,4-benzodwuazepinon-2, ^//J-etylosulfonyloetylo/^^-pirydylo/^-bromo-l^-dwuwodoro^H-l^-benzodwuazepinon^, l7^-etylosulfonyloetylo/-57o-chlorofenylo/-7-chloro-1,3-dwuwodoro-2H-1f4-benzodwuazepinon-2, l7p-etylosulfonyloetylo/-57o-tolilo/-7-chloro-1f3-dwuwodoro-2H-1,4-benzodwuazepinon-2, 17|3-etylosulfonyloetylo/-57o-chlorofenylo/-7-nitro-1,3-dwuwodc 0-2H-1,4-benzodwuazepinon-2, 17/J-propylosulfonyloetylo/-5-fenylo-7-chloro-1,3-dwuwodoro-2H-1,4-benzodwuazepinon-2, 17j3-propylosulfonyloetylo/-5-fenylo/-7-nitro-1,3-dwuwodoro-2H-1,4-benzodwuazepinon-2, l7/J-izopropylosulfonyloetylo/-57o-chlorofenylo/-7-chloro-1,3-dwuwodoro-2H-1,4-benzodwuazepinon-2, l7j3-izopropylosulfonyloetylo/-5-o-tolilo/-7-chloro-1f3-dwuwodoro-2H-1,4-benzodwuazepinon-2, l70-izopropylosulfonyloetylo/-57o-chlorofenylo/-7-nitro-1,3-dwuwodoro-2H-1,4-benzodwuazepinon-2, 177-metylosulfonylopropylo/-5-fenylo-7-chloro-1,3-dwuwodoro-2H-1,4-benzodwuazepinon-2, 177-metylosulfonylopropylo/-5-fenylo-7-nitro-1,3-dwuwodoro-2H-1,4-benzodwuazepinon-2, l77-metylosulfonylopropylo/-57o-fluorofenylo/-7-chloro-1,3-dwuwodoro-2H-1,4-benzodwuazepinon-2,70 900 3 lV7-metylosulfonylopropylo/-57o-chlorofenylo/-7-chloro-1,3 177-metylosulfonylopropylo/-5-/o-tolilo/-7-chloro-1,3-dwuwodoro-2H-1,4-benzodwuazepinon-2, lV7-metylosulfoiiylopropylo/-57o-chlorofenylo/-/-nitro-1,3 1Ty-etylosulfonylopropylo/-5-fenylo-7-chloro-1,3-dwuwodoro-2H-1 ,4-benzodwuazepinon-2, l77^tylosulfonylopropylo/-5-fenylo-7-nitro-1,3 l77^tylosulfonylopropylo/-5-fenylo-7-trójfluorometylo-1r3-dwuwodoro-2H-1,4-benzodwuazepinon-2, l77-etylosulfonylopropylo/-5-fenylo-7-bromo-1,3-dwuwodoro-2H-1,4-benzodwuazepinon-2, l77-etylosulfonylopropylo/-572'-pirydylo/-7-chloro-1,3-dwuwodoro-2H-1 ,4-benzodwuazepinon-2, l77^tylosulfonylopropylo/-57o-fluorofenylo/-7-chloro-1,3 177-etylosulfonylopropylo/-572'-pirydyk/-7-bromo-1,3-dwuwodoro-2H-1,4-benzodwuazepinon-2, 177-etylosulfonylopropylo/-57o-chlorofenylo/-7-chloro-1,3-dwuwodoro-2H-1,4-benzodwuazepinon-2, 177-etylosulfonylopropylo/-57o-tolilo/-7-chloro-1 ,3-dwuwodoro-2H-1 ,4-benzodwuazepinon-2, l77-etylosulfonylopropylo/-57o-chlorofenylo/-7-nitro-1,3-dwuwodoro-2H-1f4-benzodwuazepinon-2# l77-etylosulfonylopropylo/-57o-trójfluorometylofenylo/-7-^ l7/3-metylosulfinyloetylo/-5-fenylo-7-chloro-1,3 170-metylosulfinyloetylo/-5-fenylo-7-cyjano-1 f3-dwuwodoro-2H-1,4-benzodwuazepinon-2, 170-metylosulfinyloetylo/-5-fery lo-7-nitro-1,3-dwuwodoro-2H-1,4-benzodwuazepinon-2, l7j3-metylo$ulfinyloetyloA5-fenylo-7-metoksylo-1,3-dwuwodoro-2H-1,4-benzodwuazepinon-2, 17/3-mety losulfinyloetylo/-5-fenylo-7-trójfluorometylo-1,3-dwuwodoro-2H-1,4-benzodwuazepinon-2, 17/J-metylosulfinyloetylo/-5-fenylo-7-bromo-1 ,3-dwuwodoro-2H- 1,4-benzodwuazepinon-2, 17/J-metylosulfinyloetylo/-5-fenylo-1 #3-dwuwodoro-2H-1 ,4- benzodwuazepinon-2, 17^metylosulfinyloetylo/-5-/o-fluorofenylo/-7-chloro-1,3-dwuwodoro- 2H-1 ,4-benzodwuazepinon-2, 17^-metylosulfinyloetylo/-572'-pirydylo/-7-bromo-1/3-dwuwodoro-2H- 1,4-benzodwuazepinon-2, 17/3-metylosulfinyloetylo/-57o-chlorofenylo/-7-chloro-1f3-dwuwodoro-2H- 1,4-benzodwuazepinon-2, l7j3-metylosulfinyloetylo/-57o-tolilo/-7-chloro-1,3-dwuwodoro-2H-1,4- benzodwuazepinon-2, l7j3-metylosulfinyloetylo/-57o-chlorofenylo/-7-nitro-1,3-dwuwodoro-2H- 1,4-benzodwuazepinon-2, 17/3-metylosulfinyloetylo/-57o-trójfluorometylofenylo/-7-chloro-1,3- dwuwodoro-2H-1,4-benzodwuazepinon-2, 1-/0-etylosulfiny loetylo/-5-fenylo-7-chloro-1,3-dwuwodoro-2H-1 ,4- benzodwuazepinon-2, 17j3-etylosulfinyloetylo/-5-fenylo-7-cyjano-1,3-dwuwodoro-2H-1,4- benzodwuazepinon-2, 17j3-etylosulfinyloetylo/-5-fenylo-7-nitro-1f3-dwuwodoro-2H-1,4- * benzodwuazepinon-2, 17/3-ety losulfinyloety lo/-5-fenylo-7-trójfluorometylo-1,3-dwuwodoro-2H- benzodwuazepinon-2, 17/3-etylosulfinyloety lo/-5-fenylo-7-bromo-1,3-dwuwodoro-2H-1,4-benzodwuazepinon-2, 17j3-etylosulfinyloetylo/-5-/2'-pirydylo/-7-chloro-1,3-dwuwodoro-2H-1,4- benzodwuazepinon-2, 17/3-ety losulfinyloetylo/-5-/o-fluorofenylo/-7-chloro-1,3-dwuwodoro-2H- 1 ,4-Lenzodwuazepinon-2, ^/^-etylosulfinyloetyloAS-^^pirydylo/^-bromo-l^-dwuwodoro^H- 1,4-benzodwuazepinon-2, 17^-etylosulfinyloety lo/-5-/o-chlorofenylo/-7-chloro-1,3-dwuwodoro-2H- 1,4-benzodwuazepinon-2, l7j3-etylosulfinyloetylo/-57o-tolilo/-7-chloro-1,3-dwuwodoro-2H- 1,4-benzodwuazepinon-2, 17^-etylosulfinyloetylo/-5-/o-chlorofenylo/-7-nitro-1,3-dwuwodoro-2H- 1,4-benzodwuazepinon-2,4 70 900 l7/J-etylo$ulfinyloetylo/-5-/o-trójfluorometylofenylo/-7-chloro-1,3- dwuwodoro-2H-1,4-benzodwuazepinon-2, 1 -/0-propylosulfinyloetylo/-5-fenylo-7-chloro-1,3-dwuwodoro-2H-1 ,4- benzodwuazepinon-2, 17j3-propylosulfinyloetylo/-5-fenylo-7-nitro-1,3-dwuwodoro-2H-1,4- benzodwuazepinon-2, 17(3-propylosulfinyloetylo/-5-/o-fluorofenylo/-7-chloro-1,3-dwuwodoro- 2H-1,4-benzodwuazepinon-2, 1-/)3-propylo$ulfinyloetylo/-5-/o-chlorofenylo/-7-chloro-1#3-dwuwodoro- 2H-1,4-benzodwuazepinon-2, 1-//J-propylosulfinyloetylo/-5-/o-tolilo/-7-chloro-1,3-dwuwodoro-2H- 1,4-benzodwuazepinon-2, 1 -/0-propylosulfinyloetylo/-57o-chlorofenylo/-7-nitro-1,3-dwuwodoro-2H-1 ,4- benzodwuazepinon-2, 1-//3-izopropylo$ulfinyloetylo/-5-/o-fluorofenylo/-7-chloro-1,3-dwuwodoro- 2H-1,4-benzodwuazepinon-2, 1 -/7-metylosulfinylopropylo/-5-fenylo-7-chloro-1,3-dwuwodoro-2H- 1,4-benzodwuazepinon-2f 1-/7-metylosulf inylopropylo/-5-fenylo-7-nitro-1,3-dwuwodoro-2H- 1,4-benzodwuazepinon-2, 1-/7-mety losulfinylopropylo/-5-fenylo-7-trójfluorometylo-1f3-dwuwodoro-2H- 1,4-benzodwuazepinon-2, 1 -/7-mety losulfinylopropy lo/-5-feny lo-7-bromo-1,3-dwuwodoro-2H- 1,4-benzodwuazepinon-2, 1-/7-metylosulfinylopropylo/-3-metylo-5-fenylo-7-chloro-1,3-dwuwodoro- 2H-1,4-benzodwuazepinon-2, 1-/7-metylosulfinylopropylo/-5-/o-fluorofenylo/-7-chloro-1,3-dwuwodoro- 2H-1,4-benzodwuazepinon-2, o 1 -/7-metylosulfinylopropylo/-572'-pirydylo/-7-bromo-1,3-dwuwodoro- 2H-1,4-benzodwuazepinon-2, 1-/7-metylosulfinylopropylo/-5-/o-chlorofenylo/-7-chloro-1,3-dwuwodoro- 2H-1 ,4-benzodwuazepinon-2, 1-/7-metylosulfinylopropylo/-5-/o-tolilo/-7-chloro-1,3-dwuwodoro-2H- 1,4-benzodwuazepinon-2, 1-/7-mety losulfinylopropylo/-5-/o-chlorofenylo/-7-nitro-1,3-dwuwodoro-2H- 1,4-benzodwuazepinon-2, 1 -/7-ety losulfiny lopropylo/-5-fenylo-7-chloro-1,3-dwuwodoro-2H- 1,4-benzodwuazepinon-2, 1 -/7-ety losulfiny lopropylo/-5-fenylo-7-nitro-1,3-dwuwodoro-2H- 1,4-benzodwuazepinon-2, 1-/7-ety losulfinylopropylo/-5-fenylo-7-trójfluorometylo-1,3-dwuwodoro- 2H-1,4-benzodwuazepinon-2, 1-/7-ety losulfiny lopropy lo/-5-fenylo-7-bromo-1,3-dwuwodoro-2H- 1,4-benzodwuazepinon-2, 1-/7-etylosulfinylopropylo/-5-/o-fluorofenylo/-7-chloro-1,3-dwuwodoro-2H- 1,4-benzodwuazepinon-2, 1-/7-etylosulfinylopropylo/-5-/2'-pirydylo/-7-bromo-1,3-dwuwodoro-2H- 1,4-benzodwuazepinon-2, 1-/7-etylosulfinylopropylo/-5-/o-chlorofenylo/-7-chloro-1,3-dwuwodoro-2H- 1,4-benzodwuazepinon-2, 1-/7-etylosulfinylopropylo/-5-/o-tolilo/-7-chloro-1,3-dwuwodoro-2H- 1,4-benzodwuazepinon-2, 1-/7-etylosulfinylopropylo/-5-/o-chlorofenylo/-7-nitro-1,3-dwuwodoro- 2H-1,4-benzodwuazepinon-2, 1-/7-etylosulfinylopropylo/-5-/o-trójfluorometylofenylo/-7-chloro- 1,3-dwuwodoro-2H-1,4-benzodwuazepinon-2,70 900 5 l7^metylosulfonyloetylo/-57o,o'-dwufluorofenylo/-7-chloro-1,3- dwuwodoro -2H-1,4-benzodwuazepinon-2, 17/3-metylosulfonyloetylo/-5-/o,o'-dwuchlorofenylo/-7-chloro-1,3- dwuwodoro-2H-1,4-benzodwuazepinon-2, 17/J-metylosulfinyloetylo/-5-/o,o'-ksylilo/-7-chloro-1,3-dwu\A«)doro- 2H-1,4-benzodwuazepinon-2, 17/J-metylosulfonyloetylo/-57o-fluoro-p-chlorofenylo/-7-chloro-1,3- dwuwodoro-2H-1,4-benzodwuazepinon-2, 17/J-etylosulfonyloetylo/-57o/o'-dwufluorofenylo/-7-chloro-1,3- dwuwodoro-2H-1,4-benzodwuazepinon-2, 17/J-etylosulfonyloetylo/-57o,ó'-dwuchlorofenylo/-7-chloro-1 ,3- dwuwodoro-2H-1,4-benzodwuazepinon-2, 17j3-etylosulfonyloetylo/-57o-fluoro-o'-chlorofenylo/-7-chloro-1,3- dwuwodoro-2H-1,4-benzodwuazepinon-2, 17)3-izopropylosulfonyloetylo/-57o,o'-dwuchlorofeny lo/-7-chloro-1,3- dwuwodoro-2H-1,4-benzodwuazepinon-2, 177-metylosulfonylopropylo/-57o,o'-dwuchlorofenylo/-7-chloro-1,3- dwuwodoro-2H-1,4-benzodwuazepinon-2, 177-etylosulfonylopropylo/-5-/o,o'-dwufluorofenylo/-7-chloro-1,3- dwuwodoro-2H-1,4-benzodwuazepinon-2, l77^tylosulfonylopropylo/-5-/o,o' dwuwodoro-2H-1,4-benzodwuazepinon-2, 1-/7-metylosulfinyloetylo/-57o,o,-dwufluorofenylo/-7-chloro-1,3- dwuwodoro-2H-1,4-benzodwuazepinon-2, 1-/7-metylosulfinyloetylo/-5/o,o'-dwuchlorofenylo/-7-chloro-1,3- dwuwodoro-2H-1,4-benzodwuazepinon-2, 17j3-metylosulfinyloetylo/-57oro'-ksylilo/-7-chloro-1,3-dwuwodoro- 2H-1,4-benzodwuazepinon-2, 17j3-etylosulfonylo/-57o-metylo-p-chlorofenylo/-7-chloro-1,3-2H- dwuwodoro-1,4-benzodwuazepinon-2, 17/3-metylosulfonyloety lo/-57p-metylo-o-chlorofenylo/-7-chloro-1,3- dwuwodoro-2H-1,4-benzodwuazepinon-2, 170-etylosulfinyloety lo/-57o,o'-dwufluorofenylo/-7-chloro-1,3- dwuwodoro-2H-1,4-benzodwuazepinon-2, 17j3-etylosulfinyloetylo/-57o,o'-dwuchlorofenylo/-7-chloro-1,3- dwuwodoro-2H-1,4-benzodwuazepinon-2, l-ZY-metylosulfinylopropylo/B/o^^dwuchlorofenylo/^-chloro-l^- dwuwodoro-2H-1,4-benzodwuazepinon-2, 1 -/7-etylosu lfinylopropylo/-57o,o'-dwufluorofenylo/-7-chloro-1,3- dwuwodoro-2H-1,4-benzodwuazepinon-2, l77-etylosulfJnylopropylo/-57o,o'-dwuchlorofenylo/-7-chloro-1,3- dwuwodoro-2H-1,4-benzodwuazepinon-2.Tak otrzymane pochodne benzodwuazepiny o wzorze 1 i la tworza farmakologiczne dopuszczalne sole addycyjne z kwasami. Odpowiednimi kwasami nieorganicznymi i organicznymi sa: kwas solny, bromowodorowy, siarkowy, fosforowy, azotowy, octowy, maleinowy, fumarowy, winowy, bursztynowy, cytrynowy, kamforosulfonowy, etanosulfonowy, askorbinowy, mlekowy itp.Pochodne benzodwuazepiny o wzorze 1 i la lub ich dopuszczalne sole addycyjne z kwasami maja zastosowanie jako srodki uspokajajace, rozluzniajace miesnie, nasenne i przeciwkonwulsyjne.Przykladowo, 17j3-metylosulfonyloetylo/-5-o-fluorofenylo/-7-chloro-1,3-dwuwodoro-2H-1,4-benzodwuaze- pinon-2 i 170-metylosulfinyloety lo/-5-fenylo-7-chloro-1,3-dwuwodoro-2H-1,4-benzodwuazepinon-2 wykazuja wlasnosci antykonwulsyjne, rozluzniajace miesnie i wlasciwosci kwasu szesciobarbitalowego przy nizszej tok¬ sycznosci. Wlasciwosci farmakologiczne zwiazków otrzymywanych sposobem wedlug wynalazku sa znacznie silniejsze od wlasciwosci pokrewnych im zwiazków chemicznych, na przyklad ehlorodwuazepinotlenku, czyli 2-:~' -metyloamino-5-fenylo-7-chloro-3H-1,4-benzodwuazepino-4-tlenku.Benzodwuazepiny i,ich sole otrzymywane sposobem wedlug wynalazku poddaje sie doustnie lub pozajeli¬ towe Dawke terapeutyczna dostosowuje sie do indywidualnych potrzeb i stosuje sie ja w postaci stalej i cieklej, w takich formach jak tabletki, drazetki, kapsulki, zawiesiny, roztwory, eliksiry i podobne6 70900 Ponliize przyklady ilustruja sposób wedlug wynalazku nie ograniczajac jago zakresu.Przyklad I. Roztwór 1 g 6»fenylo-7-chloro-1,3-dwuwodoro-2H-1,4-benzodwuazepinonu«2 w 15ml N,N^wum*tyloformamldu dodaja sie do zawiesiny 0,3 g metanolu sodu w 15 ml N,N-dwumetyloformamidu I miftanine te ogrzewa tle w temperaturze 50-60°C wciagu 1 godziny. Nastepnie mieszanine reakcyjna chlodzi sie i dodaje roztwór 2 ml chlorku 0-metylosulfinyloetylu w 10 ml toluenu w temperaturze ponizej 10°C, po czym reagtnty miesza sie w temperaturze pokojowej w ciagu 30 minut, a nastepnie w temperaturze 80-90°C wciagu 5 godzin. Po zakonczeniu mieszania wlewa sie mieszanine reakcyjna do wody z lodem i ekstrahuje chlorkiem metylenu. Ekstrakty chlorku metylenu laczy sie i suszy bezwodnym siarczanem sodowym, a nastepnie odpedza rozpuszczalnik pod zmniejszonym cisnieniem. Pozostalosc pozostawia sie do wykrystalizowania. Po rekrystalizacji z octanu etylu otrzymuje sie bezbarwne krysztaly 1-//3-metylosulfinyloetylo/-5-fenylo-7-chloro-1,3 . -dwuwodoro-2H-1,4-benzodwuazepinonu-2 o temperaturze topnienia 166-167°C.Przyklad II. Postepujac analogicznie jak w przykladzie I, ale stosujac zamiast chlorku 0-metylósulfi- nyloetalu chlorek 0-metylosulfonyloetylu otrzymuje sie 1-//3-metylosUlfonyloetylo/-5-fenylo-7-chloro-1,3-dwuwo- doro-2H-1,4-benzodwuazepinonu-2 o temperaturze topnienia 160-161 °C.Analogicznie otrzymuje sie nastepujace zwiazki: 170-metylosulfonyloetylo/-57o-fluorofenylo/-7-chloro-1,3-dwuwodoro-2H- 1,4-benzodwuazeplnon-2, temperatura topnienia 155—156°C; 17/J*tylosulfonyloetylo/-57o-f1uorofenylo/-7-chloro-1,3-dwuwodoro-2H- v 1,4-benzodwuazepinon-2, temperatura topnienia 122,5-123°C; chlorowodorek 17/3-n-propylosulfonyloetylo/-57o-fluorofenylo/-7-chloro-1,3- dwuwodoro-2H-1,4-benzodwuazepinonu-2, temperatura topnienia 186,5-187°C (rozklad); chlorowodorek 170-izo-propylosulfonyloetylo/-57o-fluorofenylo/-7-chloro-1,3- dwuwodoro-2H-1,4-benzodwuazepinonu-2, temperatura topnienia 200,5—201,2°C (rozklad); 170-etylosulfonyloetylo/-5-fenylo-7-chloro-1,3-dwuwodoro-2H-1,4- benzodwuazepinon-2, temperatura topnienia 150—151 °C; 17^-n-propy losulfonyloetylo/-5-fenylo-7-chloro-1,3-dwuwodoro-2H-1,4- benzodwuazepinon-2, temperatura topnienia 143—143,5°C; 170-izo-propylosulfonyloetylo/-5-fenylo-7-chloro-1,3-dwuwodoro-2H-1,4- benzodwuazepinon-2, temperatura topnienia 183—184°C; 17P-metylosulfinyloetylo/-5-fenylo-7-nitro-1,3-dwuwodoro-2H-1,4- benzodwuazepinon-2, temperatura topnienia 170—172°C. PL PL
Claims (4)
1. Zastrzezenia patentowe 1. Sposób wytwarzania nowych pochodnych benzodwuazepiny o wzorze 1, w którym Ri oznacza atom wodoru, atom chlorowca, grupe nitrowa, grupe cyjanowa, nizszy rodnik a IkoksyIowy lub rodnik trójfluoromety- lowy, R2 oznacza grupe pirydylowa lub grupe o wzorze 2, w którym R5 i R6 oznaczaja niezaleznie od siebie atom wodoru, atom chlorowca, nizszy rodnik alkilowy, o 1—2 atomach wegla lub rodnik trójfluorometylowy, R3 oznacza atom wodoru lub nizszy rodnik alkilowy o 1-4 atomach wegla, R4 oznacza nizszy rodnik alkilowy o 1-4 atomach wegla, rodnik cykloalkilowy o 3—6 atomach wegla, rodnik cykloalkiloalkilowy, w którym czesc cykloalkilowa zawiera 3-6 atomów wegla, a czesc alkilowa 1-4 atomów wegla, rodnik arylowy lub rodnik aryloalki Iowy, m jest równe 1 lub 2, a n jest liczba calkowita 1—4 oraz ich soli, znamienny tym, ze niepodstawiona w pozycji 1 pochodna benzodwuazepiny lub jej sól o wzorze 3, w którym Ri, R2 i Ra maja znaczenie podane powyzej poddaje sie reakcji ze zwiazkiem o wzorze Cl—CnH2n—S/0/m—R4, w którym R4, m i n maja znaczenie podane powyzej.
2. Sposób wedlug zastrz. 1, znamienny tym, ze reakcje prowadzi sie w rozpuszczalniku lub mieszaninie rozpuszczajników, w obecnosci alkalicznego srodka kondensujacego.
3. Sposób wedlug zastrz. 2, znamienny tym, ze jako alkaliczny srodek kondensujacy stosuje sie wodorek sodowy, wodorek litowy, wodorotlenek potasowy, amidek sodowy, amidek potasowy, amidek litowy, butylolit, metanolan sodu lub etanolan sodu.
4. Sposób wedlug zastrz. 2, znamienny tym, ze jako rozpuszczalnik stosuje sie benzen, toluen, ksylen, dwumetyloformamid, dwumetylosulfotlenek, metyloetyloketon lub ich mieszaniny.7oroo S(0)m-R4 Wzór 1 Cn.H2n. Wzór 1a Ri C=N CH-R: V/^N '^0 Wzór 2 Wzór 3 PL PL
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP969170A JPS4910954B1 (pl) | 1970-02-03 | 1970-02-03 | |
| JP1053370A JPS4834600B1 (pl) | 1970-02-05 | 1970-02-05 | |
| JP5553070A JPS4831119B1 (pl) | 1970-06-24 | 1970-06-24 | |
| JP5552970A JPS4831118B1 (pl) | 1970-06-24 | 1970-06-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL70900B1 true PL70900B1 (en) | 1974-04-30 |
Family
ID=27455232
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL1971145964A PL70900B1 (en) | 1970-02-03 | 1971-02-02 | Benzodiazepine derivatives processes for producing them and compo sitions containing them[gb1309948a] |
Country Status (13)
| Country | Link |
|---|---|
| BE (1) | BE762404A (pl) |
| CA (1) | CA970368A (pl) |
| CH (3) | CH549033A (pl) |
| DE (1) | DE2166473A1 (pl) |
| DK (1) | DK134018B (pl) |
| FI (1) | FI52081C (pl) |
| FR (1) | FR2081482B1 (pl) |
| GB (1) | GB1309948A (pl) |
| IL (1) | IL36121A (pl) |
| NL (1) | NL169072C (pl) |
| NO (1) | NO131031C (pl) |
| PL (1) | PL70900B1 (pl) |
| SE (1) | SE364714B (pl) |
-
1971
- 1971-01-06 CH CH1648473A patent/CH549033A/xx not_active IP Right Cessation
- 1971-01-27 DK DK35571AA patent/DK134018B/da not_active IP Right Cessation
- 1971-01-28 NO NO300/71A patent/NO131031C/no unknown
- 1971-01-28 FI FI710234A patent/FI52081C/fi active
- 1971-01-29 FR FR7103060A patent/FR2081482B1/fr not_active Expired
- 1971-02-01 DE DE19712166473 patent/DE2166473A1/de active Pending
- 1971-02-01 CH CH144371A patent/CH578543A5/xx not_active IP Right Cessation
- 1971-02-01 CH CH1089574A patent/CH581632A5/xx not_active IP Right Cessation
- 1971-02-02 CA CA104,284A patent/CA970368A/en not_active Expired
- 1971-02-02 PL PL1971145964A patent/PL70900B1/pl unknown
- 1971-02-02 IL IL36121A patent/IL36121A/xx unknown
- 1971-02-02 BE BE762404A patent/BE762404A/xx not_active IP Right Cessation
- 1971-02-02 SE SE01297/71A patent/SE364714B/xx unknown
- 1971-02-02 NL NLAANVRAGE7101382,A patent/NL169072C/xx not_active IP Right Cessation
- 1971-04-19 GB GB2082771A patent/GB1309948A/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| IL36121A (en) | 1975-08-31 |
| NO131031B (pl) | 1974-12-16 |
| FI52081B (pl) | 1977-02-28 |
| CH581632A5 (pl) | 1976-11-15 |
| SE364714B (pl) | 1974-03-04 |
| DK134018C (pl) | 1977-01-31 |
| DE2104571A1 (de) | 1971-08-05 |
| GB1309948A (en) | 1973-03-14 |
| DE2104571B2 (de) | 1976-03-04 |
| NL7101382A (pl) | 1971-08-05 |
| FR2081482B1 (pl) | 1975-10-10 |
| FI52081C (fi) | 1977-06-10 |
| FR2081482A1 (pl) | 1971-12-03 |
| DE2166473A1 (de) | 1974-02-21 |
| BE762404A (fr) | 1971-07-16 |
| IL36121A0 (en) | 1971-04-28 |
| CH549033A (de) | 1974-05-15 |
| CH578543A5 (pl) | 1976-08-13 |
| NO131031C (pl) | 1975-03-25 |
| NL169072C (nl) | 1982-06-01 |
| CA970368A (en) | 1975-07-01 |
| DK134018B (da) | 1976-08-30 |
| NL169072B (nl) | 1982-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4818756A (en) | 2-pyrimidinyl-1-piperazine derivatives, processes for their preparation and medicaments containing them | |
| US3778433A (en) | Process for producing benzodiazepine derivatives | |
| US3299053A (en) | Novel 1-and/or 4-substituted alkyl 5-aromatic-3h-1, 4-benzodiazepines and benzodiazepine-2-ones | |
| US3296252A (en) | Tetracyclic diazepinone compounds | |
| CS244409B2 (en) | Method of benzodiazepine derivative production | |
| US3711509A (en) | 5-phenyl-1h-1,5-benzodiazepine-2,4-(3h,5h)-diones | |
| US4002755A (en) | Triazoloquinazolines | |
| PL70900B1 (en) | Benzodiazepine derivatives processes for producing them and compo sitions containing them[gb1309948a] | |
| US4183932A (en) | Fused quinazolinones and preparation thereof | |
| PL88788B1 (en) | Triazolo-isoindole and triazolo-isoquinoline derivatives and their manufacture and uses[gb1477302a] | |
| US3244698A (en) | 1, 4-benzodiazepines | |
| CA1162190A (en) | Carbamoyloxyamino-1,4-benzodiazepines, process for their preparation and medicaments containing these compounds | |
| US3852300A (en) | CERTAIN 6-PHENYL-4H-S-TRIAZOLO{8 1,5-a{9 {8 1,4-BENZODIAZEPINES{9 | |
| Bogatskii et al. | The Present State of the Chemistry of 1, 4-Benzodiazepines | |
| PL94512B1 (pl) | Sposob wytwarzania nowych pochodnych benzodwuazepiny | |
| US3808318A (en) | 1,2,3-benzotriazin-4(3h)-ones | |
| US3707538A (en) | 1,5,7-trisubstituted-3-hydroxy-1h-1,5-benzodiazepine-2,4-(3h,5h)-diones | |
| US3923803A (en) | 2(1H)-Quinozalinones and process therefor | |
| US3192200A (en) | 1-cycloalkyl methyl derivatives of 1, 4-benzodiazepine | |
| US3721666A (en) | 1-(phenyl or pyridyl)-4-(alkyl or alkenyl)-3h-1,4-benzodiazepine-2,5-(1h,4h)-diones | |
| US4010154A (en) | Benzodiazepinones | |
| US3297685A (en) | Process for the preparation of 2-oxo benzodiazepines | |
| US3752806A (en) | Benzodiazepines | |
| US3795702A (en) | 2-substituted-p-nitro-anilines | |
| US3944579A (en) | 2-Amino-5-phenyl-4H-3,5-dihydro-1,5-benzodiazepin-4-ones and salts thereof |